# INTERIM REPORT
# APR–JUN 2026

# GROWTH TRAJECTORY CONTINUES

## SIGNIFICANT EVENTS DURING THE SECOND QUARTER 2026 (APR – JUN)

- Mentice announced on June 29 the receipt of two orders with a total value of USD 2.4M from one of the Top 20 Global MedTech Companies within Interventional Cardiology, focused on Structural Heart Disease.

## SECOND QUARTER 2026 (APR – JUN)

- Net sales totaled 79.6 (63.4) MSEK. Organic growth was 28.1%, while growth amounted to 25.5% after FX effects.
- Order intake amounted to 78.6 (57.6) MSEK. Organic growth was 41.3%, while growth amounted to 36.6% after FX effects.
- Earnings before interest, tax, depreciation and amortization (EBITDA) improved to 6.3 (-8.1) MSEK.
- Net income for the period reached -0.9 (-17.6) MSEK.
- Earnings per share (EPS) amounted to -0.03 (-0.69) SEK.
- Cash flow from operating activities improved to 8.3 (-7.3) MSEK.

## SIX MONTHS 2026 (JAN – JUN)

- Net sales totaled 141.7 (117.7) MSEK. Organic growth was 27.3%, while growth amounted to 20.4% after FX effects.
- Order intake amounted to 137.6 (101.0) MSEK. Organic growth was 46.5%, while growth amounted to 35.9% after FX effects.
- The order book at the end of the period was 128.1 (112.0) MSEK. Organic growth was 14.5%, while growth amounted to 14.1% after FX effects.
- Earnings before interest, tax, depreciation and amortization (EBITDA) amounted to -2.9 (-27.3) MSEK.
- Net income for the period was -17.3 (-45.1) MSEK.
- Earnings per share (EPS) amounted to -0.62 (-1.76) SEK.
- Cash flow from operating activities totaled 34.8 (-10.6) MSEK.

# COMMENTS BY THE CEO FRANS VENKER

**Growth trajectory continues**

In the second quarter of 2026, Mentice sales and order intake continued to improve in line with our expectations. There is consistent and growing interest from the Medical Device Industry in our simulation solutions, and we remain focused on delivering on the high number of development projects to drive our growth trajectory.

Net sales in the quarter totaled SEK 80 million (63M), a currency comparable growth of 28 percent, representing a net growth of 26 percent. The growth is driven by our broad customer base in the Medical Device Industry (MDI) segment, which grew 30 percent. Net sales for the Healthcare Systems (HCS) segment remained mostly flat year-over-year. Our strategic approach to HCS remains under development with a medium- to long-term time horizon, but we remain optimistic about its potential.

The EMEA market continued to perform well with 36 percent growth in net sales. In the APAC region net sales doubled compared to the second quarter in the previous year, albeit from low levels of activity. We see current levels as a strong base to further build on our presence in the region. In the Americas net sales increased 8 percent. The Americas remains our core market and the activity remains strong, which is especially reflected in our order intake.

In total, currency comparable order intake grew 41 percent to SEK 79 million (58M), resulting in a net 37 percent growth. The Americas made a significant contribution with order intake growing 55 percent in the region. Most of the orders were related to project development. Our efforts to identify market trends and position our solutions to solve medical device challenges have put us in a fortunate position. The Medical Device Industry continues to turn to us for our tailored solutions and the realism of our simulations, and we are gradually increasing capacity while improving efficiency to meet this demand. At the end of June, we received orders totaling USD 2.4 million from one of the world's top 20 companies in this sector.

**Same business, different company**

This time last year, Mentice announced a series of strategic initiatives including a global restructuring of the organization, a rights issue and a review of our strategic priorities. Today, Mentice is leaner, faster and better equipped, with a lower cost base and a team ready to capture the opportunities ahead. Some effects are already visible in our financial reporting, with EBITDA reaching SEK 6 million (-8M) in the quarter, and with a significant improvement in operating cash flow for the first half year of 2026.

The strategic initiatives from last year have also affected the company in other ways. In the past months we have participated in 14 conferences globally, both to stay updated on clinical developments and to showcase our technology and products. We are met with interest from partners, customers and healthcare professionals alike, and it is gratifying to see our focus paying off.

This month we are showing our products at the Society of Neurointerventional Surgery (SNIS) in Seattle, WA and the Society of Robotic Surgery (SRS) annual meeting in Hollywood, FL. It is an exciting opportunity to meet the leaders in this space. Robotic innovations are of strategic interest to Mentice, and research activity is accelerating across this sector.

On the product side, we recently introduced Vascular Twin® Neuro, allowing the integration of real patient anatomies into hands-on training procedures such as aneurysm treatment on the VIST® G7 platform. Vascular Twin Neuro enables teams to create simulated cases on the fly and debrief live cases.

In June, we also announced a co-marketing partnership with Siemens Healthineers, integrating Ankyras® into their ARTIS Icono systems and expanding Ankyras® global reach via Siemens Healthineers network.

**Full focus on delivery**

Last month we gathered all Mentice employees to discuss our roles, strategy, priorities, and the future of the company. I believe I speak for everyone when I say we came back energized, inspired, and with a stronger sense of working towards the same goals. Our focus remains on execution and delivery.

Finally, I want to welcome our new CFO Rick van Veen to the team, and to thank Ulrika Drotz for both her commitment during her tenure and her contribution to the position Mentice is in today. My sincere thanks also go to our global teams, partners, and customers for their continued trust in Mentice and our solutions.

**Gothenburg, July 2026**

**Frans Venker, CEO**
**Mentice**

# KEY FIGURES

| | Apr-Jun 2026 | Apr-Jun 2025 | Change | Jan-Jun 2026 | Jan-Jun 2025 | Change | RTM | Full Year 2025 |
|---|---|---|---|---|---|---|---|---|
| **Net sales, MSEK** | 79.6 | 63.4 | 25.5% | 141.7 | 117.7 | 20.4% | 303.1 | 279.1 |
| **Operating income, MSEK** | 83.0 | 64.8 | 28.1% | 149.2 | 119.7 | 24.6% | 314.1 | 284.6 |
| **Gross margin, %** | 88.9% | 90.8% | | 88.0% | 91.5% | | 91.9% | 89.8% |
| **Earnings before interest, tax, depreciation, and amortization (EBITDA), MSEK** | 6.3 | -8.1 | | -2.9 | -27.2 | | 27.8 | 3.4 |
| **EBITDA-margin, %** | 7.6% | -12.4% | | -1.9% | -22.8% | | 8.9% | 1.2% |
| **Income before tax (EBT), MSEK** | -0.4 | -17.0 | | -15.0 | -43.8 | | -1.0 | -28.3 |
| **Net income for the period, MSEK** | -0.9 | -17.6 | | -17.3 | -45.1 | | -4.6 | -32.3 |
| **Earnings per share, SEK** | -0.03 | -0.69 | | -0.62 | -1.76 | | | -1.15 |
| **Order intake, MSEK** | 78.6 | 57.6 | 36.6% | 137.6 | 101.2 | 35.9% | 322.0 | 285.1 |
| - whereof Medical Device Industry (MDI) | 72.4 | 46.3 | 56.4% | 124.2 | 88.6 | 40.2% | 290.1 | 253.9 |
| - whereof Healthcare systems (HCS) | 6.2 | 11.3 | -45.1% | 13.4 | 12.6 | 6.3% | 31.9 | 31.2 |
| **Order book (end of period), MSEK** | 128.1 | 112.3 | 14.1% | 128.1 | 112.3 | 14.1% | | 129.9 |
| **Cash-flow from operations, MSEK** | 8.3 | -7.3 | | 34.8 | -10.6 | | | -20.3 |
| **Cash at the end of the period, MSEK** | 61.1 | 25.5 | | 61.1 | 25.5 | | | 33.4 |
| **Equity/Asset ratio, %** | 41.1% | 35.7% | | 41.1% | 35.7% | | | 44.2% |
| **Average employees for the quarter and for the full year** | 110.7 | 133.7 | | 109.2 | 130.8 | | 113.0 | 123.8 |

# FINANCIAL PERFORMANCE

## NET SALES

Mentice operates in two different business areas, Medical Device Industry (MDI) and Healthcare Systems (HCS).

The MDI business area includes solutions for the world's leading manufacturers of medical devices. Mentice solutions are used by these customers for training, education, sales and marketing as well as to support medical device research.

The HCS business area includes direct and indirect sales to hospitals, with the goal of implementing solutions that assist physicians in their daily clinical practice.

The goal for Mentice is to offer solutions for the daily clinical practice before, during and after an interventional procedure, thus contributing to an increased quality of patient care.

Mentice also reports sales figures for the three geographic markets: EMEA (Europe, Middle East and Africa), APAC (Asia-Pacific Region), and Americas (North, Central and South America) and for three product areas, Mentice VIST® (including Mentice Live), Physical Sim and Ankyras®.

The group's net sales consist of sales of systems and software, service and support and sales from consultancy assignments referred to as development contracts. Software licenses sold on a perpetual basis are recognized as net sales at delivery, together with hardware, while software licenses sold under a subscription model are recognized as net sales over time.

## NET SALES PER BUSINESS AREA

Net sales increased in the second quarter, primarily driven by Business Area MDI, with growth across all three regions led by EMEA.
Sales amounted to 79.6 (63.4) MSEK. Organic growth reached 28.2%, with an FX impact of −2.7%, giving an increase of 25.5% year-on-year.

For the first six months, net sales totaled 141.7 (117.7) MSEK. Organic growth was 27.3%, with an FX impact of −6.9%, giving an increase of 20.4%.

Rolling 12-month net sales were 303.1 (261.6) MSEK. Organic growth was 25.5%, with an FX impact of −9.7%, giving an increase of 15.9% year-on-year.

**Medical Device Industry (MDI)**
Net sales within MDI amounted to 70.4 (54.1) MSEK in the second quarter. Organic growth reached 33.5%, with an FX impact of −3.3%, giving an increase of 30.2%.

EMEA contributed the largest increase, supported by both large global customers and a broader customer base.

For the first six months, organic growth reached 30.4%, with an FX impact of −8.5%, giving an increase of 21.9%.

On a rolling 12-month basis, organic growth was 37.5%, with an FX impact of −11.2%, giving an increase of 26.3%.

**Healthcare Systems (HCS)**
Net sales within HCS amounted to 9.2 (9.3) MSEK in the second quarter. Organic sales declined by 1.6%, with an FX impact of −0.3%, giving a decline of 1.9%.
For the first six months, organic growth was 9.3%, with a positive FX impact of 1.7%, giving an increase of 11.0%.

| Net sales per business area KSEK | Apr-Jun 2026 | Apr-Jun 2025 | Change | Jan-Jun 2026 | Jan-Jun 2025 | Change | RTM | Full year 2025 |
|---|---|---|---|---|---|---|---|---|
| Medical Device Industry (MDI) | 70,422 | 54,088 | 30.2% | 124,336 | 102,026 | 21.9% | 267,039 | 243,893 |
| Healthcare Systems (HCS) | 9,169 | 9,343 | -1.9% | 17,396 | 15,675 | 11.0% | 36,086 | 35,200 |
| **Total** | **79,591** | **63,431** | **25.5%** | **141,732** | **117,701** | **20.4%** | **303,125** | **279,093** |

## NET SALES PER BUSINESS AREA, ROLLING 12 MONTHS (MSEK)



## MENTICE OPERATES IN THREE REGIONS

**Net sales per region**

All three regions delivered organic growth in the second quarter, with EMEA contributing the largest increase. Americas remained the largest region.

**AMERICAS**

Net sales amounted to 41.6 (38.7) MSEK in the quarter. Organic growth reached 10.4%, with an FX impact of −2.9%, giving an increase of 7.5%.

The quarter was supported by development and software revenue.

For the first six months, revenue increased 10.8% in local currency, with an FX impact of −8.5%, giving an increase of 2.3%.

On a rolling 12-month basis, organic growth was 21.2%, with an FX impact of −11.5%, giving an increase of 9.7%.

**EMEA**

Net sales reached 24.9 (18.2) MSEK in the second quarter. Organic growth was 38.6%, with an FX impact of −2.1%, giving an increase of 36.5%.
The increase was supported by both large customers and a wider customer base.

For the first six months, revenue increased 61.1% in local currency, with an FX impact of −5.0%, giving an increase of 56.1%.

On a rolling 12-month basis, organic growth reached 38.1%, with an FX impact of −9.9%, giving an increase of 28.2%.

**APAC**

Net sales amounted to 13.1 (6.5) MSEK in the quarter. Organic growth reached 103.9%, with an FX impact of −2.9%, giving an increase of 101.0%.

The increase was partly supported by a lower prior-year base.

For the first six months, revenue increased 32.1% in local currency, with an FX impact of −4.3%, giving an increase of 27.8%.

| Net sales per region KSEK | Apr-Jun 2026 | Apr-Jun 2025 | Change | Jan-Jun 2026 | Jan-Jun 2025 | Change | RTM | Full Year 2025 |
|---|---|---|---|---|---|---|---|---|
| AMERICAS | 41,568 | 38,660 | 7.5% | 70,022 | 68,430 | 2.3% | 152,049 | 150,426 |
| EMEA | 24,897 | 18,242 | 36.5% | 48,240 | 30,906 | 56.1% | 101,631 | 84,340 |
| APAC | 13,126 | 6,529 | 101.0% | 23,470 | 18,365 | 27.8% | 49,445 | 44,327 |
| **Total** | **79,591** | **63,431** | **25.5%** | **141,732** | **117,701** | **20.4%** | **303,125** | **279,093** |

## NET SALES PER REGION, ROLLING 12 MONTHS (MSEK)



## ORDER INTAKE

**Q2 Order Intake**

Order intake momentum continued in the second quarter, with a rolling 12-month intake reaching 322.0 MSEK, reflecting organic growth of 28.7%.

During the second quarter, total order intake reached 78.6 (57.6) MSEK. Organic growth was 41.2%, with an FX impact of −4.6%, giving an increase of 36.6%.

For the first six months, orders totaled 137.6 (101.2) MSEK. Organic growth was 46.5%, with an FX impact of −10.6%, giving an increase of 35.9%.

**Medical Device Industry (MDI)**
In the second quarter, order intake amounted to 72.4 (46.3) MSEK. Organic growth was 62.9%, with an FX impact of −6.5%, giving an increase of 56.4%.
Americas and APAC contributed the largest increases in the quarter. Both regions delivered strong organic growth, while EMEA was below last year.

For the first six months, orders totaled 124.2 (88.6) MSEK. Organic growth was 47.9%, with an FX impact of −7.7%, giving an increase of 40.1%.

**Healthcare Systems (HCS)**
During the second quarter, order intake reached 6.2 (11.3) MSEK. Organic intake declined by 42.2%, with an FX impact of −2.6%, giving a decline of 44.8%.
Most order intake during the quarter came from the EMEA and APAC regions.

For the first six months, orders totaled 13.4 (12.6) MSEK. Organic growth was 9.4%, with an FX impact of −3.1%, giving an increase of 6.3%.

*It is important to note that large orders can create a substantial variance in the distribution of order intake between business areas in individual quarters. Therefore, the Company is basing the evaluation of performance on rolling 12 months or full year figures.*

| Order intake per business area KSEK | Apr-Jun 2026 | Apr-Jun 2025 | Change | Jan-Jun 2026 | Jan-Jun 2025 | Change | RTM | Full year 2025 |
|---|---|---|---|---|---|---|---|---|
| Medical Device Industry (MDI) | 72,349 | 46,246 | 56.4% | 124,213 | 88,638 | 40.1% | 290,071 | 253,926 |
| Healthcare systems (HCS) | 6,243 | 11,304 | -44.8% | 13,361 | 12,573 | 6.3% | 31,924 | 31,138 |
| **Total** | **78,592** | **57,550** | **36.6%** | **137,574** | **101,211** | **35.9%** | **321,995** | **285,064** |

## ORDER INTAKE PER BUSINESS AREA, ROLLING 12 MONTHS (MSEK)



## ORDER BOOK

The order book consists of received orders that will be recognized as net sales in upcoming periods.

The order book at the end of the period totaled 128.1 (112.3) MSEK, reflecting organic growth of 14.5%. Currency effects of −0.4% resulted in a reported increase of 14.1%.

Of the order book, 78.6 MSEK is expected to be recognized as revenue during 2026.

| MDI Order book by Region KSEK | 2026 | 2027- |
|---|---|---|
| Americas | 58,253 | 8,304 |
| EMEA | 9,008 | 11,813 |
| APAC | 3,540 | 3,872 |
| **Total MDI** | **70,801** | **23,989** |

| HCS Order Book by Region KSEK | 2026 | 2027- |
|---|---|---|
| Americas | 1,886 | 5,705 |
| EMEA | 3,831 | 11,838 |
| APAC | 2,102 | 7,979 |
| **Total HCS** | **7,819** | **25,522** |

| Total Order Book by Region KSEK | 2026 | 2027- |
|---|---|---|
| Americas | 60,139 | 14,009 |
| EMEA | 12,839 | 23,651 |
| APAC | 5,642 | 11,851 |
| **Total Order Book** | **78,620** | **49,511** |

## ORDER BOOK PER QUARTER AND BUSINESS AREA (MSEK)




## ORDER BOOK PER QUARTER AND BUSINESS AREA (MSEK)

## OTHER INCOME

Other income was 3.4 (1.4) MSEK for the quarter and for the first six months other income amounted to 7.4 (2.0) MSEK. It is related to the exchange rate's impact on the operating activities.

## GROSS PROFIT AND GROSS MARGIN

The gross profit for the second quarter was 74.2 (59.0) MSEK, corresponding to a gross margin of 88.9 (90.8)%.
For the first six months, gross profit amounted to 132.1 (109.7) MSEK, with a gross margin of 88.0 (91.5)%.

Gross margin in the second quarter decreased compared to the prior year, driven primarily by an unfavorable product mix. Gross margin is influenced by the mix of products and services sold, the balance between software licenses and hardware systems, and the regional sales mix.

## EBITDA AND EBITDA MARGIN

Earnings before interest, tax, depreciation and amortization, EBITDA, amounted to 6.3 (-8.0) MSEK for the quarter. This corresponds to an EBITDA margin of 7.6 (-12.4)% for the second quarter.

The EBITDA Margin for the quarter improved significantly due to higher revenues and an almost flat cost base compared to Q2 2025.

Earnings before interest, tax, depreciation and amortization, EBITDA, amounted to -2.9 (-27.3) MSEK for the first six months. This corresponds to an EBITDA margin of -1.9 (-22.8)%.

## OTHER EXTERNAL COSTS

Other external costs amounted to -22.4 (-21.7) MSEK during the second quarter, which equals an increase of 3.2% compared to the same period last year. Compared with the same period last year, costs for hired consulting and support, travelling and IT are higher to also deliver the higher sales. The second quarter of last year included costs of -3.2 MSEK that were incurred for the strategic workforce realignment.

Other external costs amounted to -44.1 (-41.4) MSEK during the first six months, which equals an increase of 6.4% compared to the same period last year.

## PERSONNEL COSTS

Personnel costs during the second quarter were -45.4 (-45.3) MSEK, which equals an increase of 0.3% compared to the same period last year. The second quarter of last year included costs of -4.3 MSEK that were incurred for the strategic workforce realignment.

Personnel costs during the first six months were -90.9 (-95.5) MSEK, which equals a decrease of 4.9%.

Personnel costs include capitalized costs for development of 0.7 (1.1) MSEK for the quarter and 2.0 (2.4) MSEK for the first six months.

The average number of employees amounted to 110.7 during the quarter, compared with 107 at the beginning of the year.

## CAPITALIZED EXPENSES FOR DEVELOPMENT PROJECTS

Capitalized expenses for development projects during the second quarter amounted to 1.5 (2.2) MSEK. Capitalized expenses for development projects during the first six months amounted to 3.3 (5.3) MSEK.

The capitalization is accounted for as external costs if the original cost is for consultants for development and in personnel costs if the original cost is for internal employees.

## FINANCIAL ITEMS

Net financial items for the quarter amounted to -0.7 (-0.3) MSEK. Net financial items for the first six months amounted to -1.5 (-0.3) MSEK.

## INCOME BEFORE TAX, NET RESULT FOR THE PERIOD AND EARNINGS PER SHARE

Tax on income for the second quarter was -0.5 (-0.5) MSEK. Net income for the quarter was -0.9 (-17.6) MSEK. Earnings per share were -0.03 (-0.69) SEK for the second quarter.

Tax on income for the first six months was -0.8 (-1.2) MSEK. Net income for the first six months was -17.4 (-45.1) MSEK and earnings per share were -0.62 (-1.76) SEK.

## CASH FLOW

Cash flow from operating activities before changes in working capital was 7.1 (-10.3) MSEK for the second quarter. Cash flow from change in working capital was 1.2 (3.0) MSEK. Cash flow from operating activities amounted to 8.3 (-7.3) MSEK for the quarter.

For the first six months, cash flow from operating activities amounted to 34.8 (-10.6) MSEK.

## CASH AND FINANCIAL POSITION

Cash at the end of the period was 61.1 (25.5) MSEK. The group's total assets amounted to 298.5 (268.1) MSEK. IFRS 16 affected total assets by 13.0 (18.9) MSEK. Accounts receivable increased compared to the same quarter last year and amounted to 71.4 (58.8) MSEK.

Inventories amounted to 18.5 (20.5) MSEK. Current liabilities were 168.0 (161.8) MSEK. The carrying amounts of financial assets and liabilities are considered to correspond essentially to fair value.

## INVESTMENTS

Investments during the second quarter amounted to 2.1 (3.1) MSEK, whereof 1.5 (2.2) MSEK refers to the capitalization of development costs. The remaining 0.6 (0.9) MSEK refers to investments in tangible fixed assets.

Investments during the first six months amounted to 4.2 (7.4) MSEK.

## PARENT COMPANY

The parent company is an operating company based in Gothenburg, Sweden. Net sales for the second quarter for the parent company amounted to 58.3 (42.5) MSEK. The gross margin amounted to 88.6 (85.3)% for the quarter. The net income for the period was -2.0 (-21.5) MSEK.

For the first six months net sales amounted to 97.8 (74.9) MSEK with a gross margin of 86.3 (82.1)% and the net income for the period was -19.2 (-53.6) MSEK.

## SHARE CAPITAL

The total number of shares as of June 30, 2026, was 28,125,735 (25,568,850) and the share capital was 1,406 KSEK. All shares are ordinary shares with equal voting value. The shares have a quota value of 0.05 SEK.

## DISPUTES

The group has no current disputes.

## TRANSACTIONS WITH RELATED PARTIES

In addition to receiving board fees, Board member Denis Gestin, through a related company, provided consulting services to the Company in connection with customer-related activities within the Medical Device industry and other advisory services. During the period April through June 2026 Denis Gestin received 0.26 (0.26) MSEK in fees in addition to board remuneration, and for the first six months 0.58 (0.5) MSEK.

The Company also maintains a consulting agreement with chairman of the board Göran Malmberg, related to business development and advisory services. Fees for the period April-June 2026 amounted to 0.86 (0.86) MSEK, and for the first six months 1.7 (1.7) MSEK.

Furthermore, the Company has an employment agreement with a close relative of Board member Lawrence Howell. Compensation under this agreement for the period April–June 2026 amounted to 0.2 (0.00) MSEK, and for the first six months 0.4 (0.00) MSEK.

All related party transactions were conducted on arm’s length terms.

## RISKS

Important risks and uncertainties for the group are primarily related to commercial risks with customers and suppliers, operational risks with regard to competence and security in the implementation of new medical equipment.

The financial risks are related to the global operations that the company operates. This includes changes in exchange rates and interest rates, as well as liquidity, financing, and credit.

Currency risk also arises when translating foreign net assets and earnings into Swedish kronor. Mentice overall goal is to avoid financial risk-taking as far as possible, which can arise through changes in exchange rates, interest rates and market prices, as well as liquidity, financing, and credit risks.

Exchange rate risk is divided into translation exposure and transaction exposure. Translation exposure refers to the exposure of net assets for foreign subsidiaries. Transaction exposure refers to the risks associated with purchases and net sales in foreign currency.

The group’s external sales are made in the currencies EUR and USD. In the parent company, the external sales are in EUR or USD, and most of the operating costs are in SEK. Net sales and costs in the US subsidiary are exclusively conducted in USD. Net sales and costs in the other subsidiaries are mainly in EUR or USD.

For more information about the company’s risks, see the board of directors’ report in the annual report for 2025.

## THE SHARE AND OWNERSHIP

Mentice AB (publ.) shares have been traded on Nasdaq First North Growth Market since 2019 under MNTC. According to Euroclear's official register of shareholders, Mentice had a total of 1,239 shareholders by June 30, 2026. FNCA is the company's certified advisor.

| Largest shareholders (source Euroclear 2026-06-30) Name | Number of shares | Shareholding in % |
|---|---|---|
| Karin Howell-Bidermann | 9,560,077 | 33.99% |
| Gulf Offshore Limited | 8,223,381 | 29.24% |
| Avanza Pension | 1,689,178 | 6.01% |
| Sino Delta Limited B.V. | 1,101,000 | 3.91% |
| Göran Malmberg | 782,837 | 2.78% |
| Schroders | 660,000 | 2.35% |
| Handelsbanken Liv Försäkring AB | 435,874 | 1.55% |
| Bo Perninger | 320,000 | 1.14% |
| Peter Trigarszky | 191,695 | 0.68% |
| Nordnet Pensionsförsäkring | 185,696 | 0.66% |
| 10 largest shareholders total | **23,149,738** | **82.31%** |
| Others | 4,975,997 | 17.69% |
| **Total number of shares** | **28,125,735** | **100.00%** |

## EXAMINATION BY THE AUDITORS

This report has not been reviewed by the company's auditors.

## FINANCIAL REPORTS

Interim reports and other financial reports are available on the company's website: www.mentice.com.

# AFFIRMATION

The CEO of Mentice AB (publ) hereby assures that this interim report gives a true and fair view of the Group's business, financial position and performance and describes the essential risks and uncertainty factors that the company and the companies which are part of the Group are subject to. In the event of any discrepancies between the English and Swedish versions of the report, the Swedish version shall prevail.

**Gothenburg, July 22, 2026**
**Mentice AB (publ)**

**Frans Venker**
CEO

# CONSOLIDATED INCOME STATEMENT

| KSEK | Apr-Jun 2026 | Apr-Jun 2025 | Jan-Jun 2026 | Jan-Jun 2025 | Full year 2025 |
|---|---|---|---|---|---|
| Net sales | 79,591 | 63,431 | 141,732 | 117,701 | 279,093 |
| Other income | 3,405 | 1,374 | 7,421 | 1,981 | 5,496 |
| **Operating income** | **82,997** | **64,806** | **149,154** | **119,682** | **284,589** |
| | | | | | |
| Raw materials and consumables used | -8,718 | -5,751 | -16,858 | -9,837 | -28,227 |
| Depreciation of rented assets | -93 | -87 | -199 | -148 | -341 |
| Other external expenses | -22,430 | -21,725 | -44,107 | -41,439 | -85,653 |
| Personnel expenses | -45,425 | -45,286 | -90,889 | -95,543 | -166,930 |
| Depreciation of tangible assets | -2,616 | -4,332 | -5,326 | -7,900 | -12,843 |
| Amortization and write-down of intangible assets | -3,443 | -4,326 | -6,806 | -8,309 | -18,159 |
| **Operating expenses** | **-82,726** | **-81,507** | **-164,185** | **-163,176** | **-312,153** |
| | | | | | |
| **Operating profit (EBIT)** | **271** | **-16,701** | **-15,031** | **-43,494** | **-27,565** |
| | | | | | |
| Financial income | 335 | 89 | 337 | 129 | 460 |
| Financial expenses | -998 | -435 | -1,871 | -461 | -1,165 |
| **Net financial items** | **-664** | **-346** | **-1,534** | **-332** | **-705** |
| | | | | | |
| **Earnings before tax (EBT)** | **-393** | **-17,047** | **-16,565** | **-43,825** | **-28,270** |
| Tax | -487 | -520 | -784 | -1,249 | -4,064 |
| | | | | | |
| **Net result for the year** | **-880** | **-17,567** | **-17,350** | **-45,074** | **-32,334** |
| Net result for the year attributable to: | | | | | |
| Shareholders of the parent company | -880 | -17,567 | -17,350 | -45,074 | -32,334 |
| **Earnings per share** | | | | | |
| Basic (SEK) | -0.03 | -0.69 | -0.62 | -1.76 | -1.15 |
| Diluted (SEK) | -0.03 | -0.69 | -0.62 | -1.76 | -1.15 |

# CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

| KSEK | Apr-Jun 2026 | Apr-Jun 2025 | Jan-Jun 2026 | Jan-Jun 2025 | Full year 2025 |
|---|---|---|---|---|---|
| Net result for the year | -880 | -17,567 | -17,350 | -45,074 | -32,334 |
| **Other comprehensive income** | | | | | |
| Items can be transferred to profit or loss for the year: | | | | | |
| Translation difference on translation of foreign operations | 695 | -2,151 | 2,041 | -3,104 | -4,335 |
| | | | | | |
| **Total comprehensive income for the year** | **-185** | **-19,718** | **-15,309** | **-48,178** | **-36,669** |

# CONSOLIDATED BALANCE SHEET

| KSEK | 30 Jun 2026 | 30 Jun 2025 | Full year 2025 |
|---|---|---|---|
| **Assets** | | | |
| Goodwill | 48,508 | 48,508 | 48,508 |
| Patents | 19,211 | 22,835 | 21,020 |
| Trademarks | 605 | 1,814 | 1,209 |
| Internally developed intangible assets | 37,081 | 40,829 | 38,290 |
| Tangible assets | 9,228 | 8,737 | 8,743 |
| Right-of-use assets | 14,233 | 20,150 | 17,637 |
| Deferred tax assets | 977 | 3,403 | 675 |
| **Total non-current assets** | **129,842** | **146,276** | **136,083** |
| | | | |
| Inventories | 18,472 | 20,519 | 17,762 |
| Accounts receivable | 71,447 | 58,804 | 104,813 |
| Prepaid costs and accrued income | 13,004 | 12,110 | 13,745 |
| Current tax assets | 877 | 1,037 | 2,111 |
| Other receivables | 3,798 | 3,874 | 4,131 |
| Cash and cash equivalents | 61,072 | 25,466 | 33,376 |
| **Total current assets** | **168,670** | **121,810** | **175,939** |
| **Total assets** | **298,512** | **268,086** | **312,021** |
| | | | |
| **Equity and liabilities** | | | |
| Share capital | 1,406 | 1,278 | 1,406 |
| Other paid in capital | 233,496 | 202,061 | 232,983 |
| Retained earnings | -111,322 | -107,522 | -96,013 |
| **Total equity attributable to parent company shareholders** | **123,580** | **95,817** | **138,376** |
| | | | |
| **Long-term liabilities** | | | |
| Long-term leasing liabilities | 6,894 | 10,501 | 9,326 |
| **Total long-term liabilities** | **6,894** | **10,501** | **9,326** |
| | | | |
| Accounts payable | 9,045 | 8,409 | 10,218 |
| Other liabilities | 4,201 | 3,971 | 3,919 |
| Current lease liability | 6,670 | 8,746 | 7,495 |
| Accrued expenses and deferred income | 148,121 | 140,642 | 142,687 |
| **Total current liabilities** | **168,037** | **161,768** | **164,320** |
| **Total equity and liabilities** | **298,512** | **268,086** | **312,021** |

# CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

| KSEK | Share capital | Other paid in capital | Translation reserve | Retained earnings | Total equity |
|---|---|---|---|---|---|
| **At 1 January 2025** | **1,278** | **201,728** | **663** | **-60,006** | **143,663** |
| | | | | | |
| **Transactions with owners in the group** | | | | | |
| New share issue | 128 | 30,408 | | | 30,536 |
| Issue of share options | | 847 | | | 847 |
| Exercise of share options | | | | | |
| **Net result and other comprehensive income for the year** | | | | | |
| Net result for the year | | | | -32,334 | -32,334 |
| Other comprehensive income for the year | | | -5,045 | 710 | -4,335 |
| **Total comprehensive income for the year** | | | **-5,045** | **-31,624** | **-36,669** |
| **Closing balance at 31 December 2025** | **1,406** | **232,983** | **-4,382** | **-91,630** | **138,376** |
| | | | | | |
| **At 1 January 2026** | **1,406** | **232,983** | **-4,382** | **-91,630** | **138,376** |
| | | | | | |
| **Transactions with owners in the group** | | | | | |
| New share issue | | | | | |
| Issue of share options | | 514 | | | 514 |
| Payment of share options | | | | | |
| **Net result and other comprehensive income for the year** | | | | | |
| Net result for the year | | | | -17,350 | -17,350 |
| Other comprehensive income for the year | | | 1,895 | 146 | 2,041 |
| **Total comprehensive income for the year** | | | **1,895** | **-17,204** | **-15,309** |
| **Closing balance at 30 June 2026** | **1,406** | **233,496** | **-2,488** | **-108,834** | **123,580** |

# CONSOLIDATED STATEMENT OF CASH FLOWS

| KSEK | Apr-Jun 2026 | Apr-Jun 2025 | Jan-Jun 2026 | Jan-Jun 2025 | Full year 2025 |
|---|---|---|---|---|---|
| **Operating activities** | | | | | |
| Earnings before tax | -393 | -17,047 | -16,565 | -43,825 | -28,270 |
| Adjustment for non-cash items | 8,007 | 7,492 | 15,029 | 16,063 | 33,583 |
| Income tax paid | -510 | -691 | 327 | -17 | -1,069 |
| **Cash flow from operating activities before changes in working capital** | **7,105** | **-10,247** | **-1,209** | **-27,779** | **4,244** |
| | | | | | |
| Change in trade receivables and other current assets | 4,937 | 8,693 | 37,044 | 31,808 | -19,802 |
| Change in inventories | -1,122 | -2,216 | -181 | -4,373 | -1,871 |
| Change in trade payables and other current liabilities | -2,587 | -3,507 | -897 | -10,271 | -2,870 |
| **Change in working capital** | **1,228** | **2,970** | **35,966** | **17,164** | **-24,544** |
| | | | | | |
| **Cash flow from operating activities** | **8,333** | **-7,277** | **34,756** | **-10,615** | **-20,300** |
| | | | | | |
| **Investing activities** | | | | | |
| Acquisitions of tangible assets | -680 | -2,092 | -1,310 | -2,092 | -5,128 |
| Capitalization of internally developed intangible assets | -1,479 | -2,181 | -3,328 | -5,347 | -10,328 |
| **Cash flow from investing activities** | **-2,159** | **-4,273** | **-4,638** | **-7,439** | **-15,456** |
| | | | | | |
| **Financing activities** | | | | | |
| New share issue | | | | | 31,961 |
| New share issue cost | | | | | -1,425 |
| Repayment of lease liability | -1,894 | -2,857 | -4,112 | -6,567 | -10,872 |
| **Cash flow from financing activities** | **-1,894** | **-2,857** | **-4,112** | **-6,567** | **19,664** |
| | | | | | |
| **Cash flow for the period** | **4,280** | **-14,406** | **26,007** | **-24,621** | **-16,091** |
| | | | | | |
| Opening cash balance | 56,218 | 40,550 | 33,376 | 53,586 | 53,586 |
| Translation difference on cash and cash equivalents | 574 | -678 | 1,688 | -3,499 | -4,118 |
| | | | | | |
| **Cash and bank balances at end of period** | **61,072** | **25,466** | **61,072** | **25,466** | **33,376** |

# PARENT COMPANY INCOME STATEMENT

| KSEK | Apr-Jun 2026 | Apr-Jun 2025 | Jan-Jun 2026 | Jan-Jun 2025 | Full year 2025 |
|---|---|---|---|---|---|
| Net sales | 58,309 | 42,470 | 97,758 | 74,888 | 189,695 |
| Capitalised expense for development | 1,479 | 2,002 | 3,328 | 4,889 | 9,940 |
| Other income | 3,355 | 1,133 | 7,371 | 1,740 | 5,154 |
| **Operating income** | **63,144** | **45,605** | **108,457** | **81,518** | **204,789** |
| | | | | | |
| Raw materials and consumables used | -6,625 | -4,697 | -13,406 | -9,713 | -26,034 |
| Other external expenses | -21,928 | -23,349 | -38,742 | -41,928 | -76,671 |
| Personnel expenses | -28,968 | -30,246 | -59,980 | -62,663 | -108,447 |
| Depreciation of tangible assets | -220 | -406 | -463 | -848 | -1,514 |
| Amortization and write-down of intangible assets | -3,501 | -6,808 | -6,908 | -13,273 | -28,086 |
| Exchange losses on operating receivables and liabilities | -3,135 | -1,612 | -6,745 | -6,714 | -9,090 |
| Loss on disposal of fixed assets | 0 | 0 | 0 | 0 | -1,369 |
| **Operating expenses** | **-64,376** | **-67,118** | **-126,243** | **-135,139** | **-251,211** |
| | | | | | |
| **Operating profit (EBIT)** | **-1,232** | **-21,513** | **-17,785** | **-53,621** | **-46,422** |
| | | | | | |
| Financial income | 221 | 158 | 238 | 236 | 583 |
| Financial expenses | -973 | -103 | -1,674 | -245 | -667 |
| **Net financial items** | **-751** | **55** | **-1,436** | **-9** | **-84** |
| | | | | | |
| **Result after financial items** | **-1,984** | **-21,457** | **-19,222** | **-53,630** | **-46,506** |
| | | | | | |
| **Earnings before tax (EBT)** | **-1,984** | **-21,457** | **-19,222** | **-53,630** | **-46,506** |
| | | | | | |
| Tax | 0 | 0 | 0 | 0 | -137 |
| | | | | | |
| **Net result for the year** | **-1,984** | **-21,457** | **-19,222** | **-53,630** | **-46,643** |

# PARENT COMPANY BALANCE SHEET

| KSEK | 30 Jun 2026 | 30 Jun 2025 | Full year 2025 |
|---|---|---|---|
| **Assets** | | | |
| **Intangible and tangible assets** | | | |
| Goodwill | 1,140 | 6,137 | 1,241 |
| Patents | 19,111 | 22,835 | 20,940 |
| Trademarks | 605 | 1,814 | 1,209 |
| Internally developed intangible assets | 35,883 | 39,347 | 36,929 |
| Tangible assets | 2,582 | 4,226 | 2,441 |
| **Financial assets** | | | |
| Shares in group companies | 21,886 | 21,886 | 21,886 |
| Receivables from group companies | 1,002 | 1,007 | 977 |
| Deferred tax assets | 6,615 | 6,615 | 6,615 |
| **Total non-current assets** | **88,824** | **103,868** | **92,238** |
| | | | |
| Inventories | 9,506 | 11,523 | 8,732 |
| Accounts receivables | 30,218 | 22,664 | 44,188 |
| Current receivables, group companies | 18,898 | 8,196 | 18,342 |
| Prepaid expenses and accrued income | 10,847 | 13,240 | 11,151 |
| Current tax assets | 2,777 | 2,279 | 3,170 |
| Other receivables | 3,013 | 3,330 | 3,449 |
| Cash and cash equivalents | 28,718 | 746 | 8,458 |
| **Total current assets** | **103,977** | **61,979** | **97,490** |
| **Total assets** | **192,801** | **165,846** | **189,729** |
| | | | |
| **Equity and liabilities** | | | |
| **Restricted equity** | | | |
| Share capital | 1,406 | 1,278 | 1,406 |
| Fund for development costs | 35,883 | 39,708 | 36,929 |
| **Non-restricted equity** | | | |
| Other paid in capital | 233,496 | 202,061 | 232,983 |
| Retained earnings | -179,686 | -136,868 | -134,089 |
| Net result for the year | -19,222 | -53,630 | -46,643 |
| **Total equity** | **71,879** | **52,550** | **90,587** |
| | | | |
| **Long-term liabilities** | | | |
| Liabilities to group companies | 23,093 | 770 | 689 |
| **Total long-term liabilities** | **23,093** | **770** | **689** |
| | | | |
| Accounts payable | 8,542 | 7,821 | 9,409 |
| Current liabilities, group companies | 6,075 | 6,714 | 5,237 |
| Other liabilities | 2,127 | 2,094 | 1,404 |
| Accrued expenses and deferred income | 81,085 | 95,898 | 82,402 |
| **Total current liabilities** | **97,829** | **112,527** | **98,453** |
| **Total equity and liabilities** | **192,801** | **165,846** | **189,729** |

# NOTES

## ACCOUNTING POLICIES

Mentice applies International Financial Reporting Standards (IFRS) as adopted by the EU. This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The parent company's interim report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2, Accounting for Legal Entities, issued by the Swedish Financial Reporting Board.

The accounting policies are unchanged compared to 2025.

## BASES OF VALUATION APPLIED IN THE PREPARATION OF THE FINANCIAL STATEMENTS

Assets and liabilities are recognized at historical cost except for currency derivatives, which are measured at fair value. As of June 30, 2026, the total fair value of forward contracts was 65.2 (0.0) MSEK.

## ASSESSMENTS AND ESTIMATES IN THE FINANCIAL STATEMENTS

Preparation of the financial statements in compliance with IFRS requires the company's management to make assessments, estimates and assumptions that affect the application of the accounting policies and the carrying amounts of assets, liabilities, income, and expenses. Actual outcomes may deviate from these estimates and assessments. Assumptions are reviewed on a regular basis. Changes to estimates are recognized in the period.

## FINANCIAL INSTRUMENTS, CURRENCY EXPOSURE AND RISK MANAGEMENT

Mentice uses forward exchange contracts to manage currency risk. Forward exchange contracts are used to hedge risk in accordance with the group financial policy. Mentice operations expose it to credit risk when selling to customers. Only advance payments or letters of credit are accepted for sales to new customers or to customers which are deemed to represent a high-risk exposure.

## ADJUSTMENTS, ROUNDING

Some of the financial information provided in this report has been rounded, which may affect the totals in the tables.

## ABOUT THE PARENT COMPANY

Mentice AB (publ.), company registration number 556556-4241, is a Swedish public company with its registered office in Gothenburg, Sweden.

## WARRANT PROGRAM

Mentice has two outstanding option programs for employees, with the aim of stimulating increased commitment and interest in the business and its performance. Against this background, the programs are expected to have a positive impact on the company's continued development and thus be good for the company and its shareholders.

A warrant program directed at external key opinion leaders in North America, initiated in 2023, expired out of the money. Key opinion leaders who have participated in this warrant program have paid a premium corresponding to the market value of the warrant calculated pursuant to Black & Scholes' formula. As the market value has been paid, there is no effect on the company's net income for the period or on its financial position.

## SEGMENT REPORTING

Mentice business is divided into two business areas, which reflect the group's operations, financial management and management structure. These business areas are Medical Device Industry (MDI) and Healthcare Systems (HCS).

As of Q1 2026, the Medical Device Industry (MDI) and Healthcare Systems (HCS) business areas are now also the reported business segments, replacing the previous product areas Mentice VIST®, Physical Sim, and Ankyras®. This change has been made to better reflect how the Company's operations are structured. It does not give rise to any need to restate prior figures, nor does it affect reporting in general.

The segment reporting according to IFRS 8 was earlier based on product area and the division is now based on business areas to better reflect how the business is run and followed.

## OUTCOME PER BUSINESS AREA Q2

| KSEK | Medical Device Industry (MDI) | | | Healthcare Systems (HCS) | | | Total | | |
|---|---|---|---|---|---|---|---|---|---|
| | Apr-Jun 2026 | Apr-Jun 2025 | FY 2025 | Apr-Jun 2026 | Apr-Jun 2025 | FY 2025 | Apr-Jun 2026 | Apr-Jun 2025 | FY 2025 |
| **Total Net sales** | **70,422** | **54,088** | **243,893** | **9,169** | **9,343** | **35,200** | **79,591** | **63,431** | **279,093** |
| Raw mtrl and consumables used | -7,434 | -4,286 | -24,643 | -1,377 | -1,552 | -3,925 | -8,811 | -5,838 | -28,568 |
| Gross profit | 62,988 | 49,802 | 219,250 | 7,792 | 7,791 | 31,275 | 70,780 | 57,593 | 250,525 |
| Gross profit % | 89.4% | 92.1% | 89.9% | 85.0% | 83.4% | 88.9% | 88.9% | 90.8% | 89.8% |

## OUTCOME PER BUSINESS AREA YTD

| KSEK | Medical Device Industry (MDI) | | | Healthcare Systems (HCS) | | | Total | | |
|---|---|---|---|---|---|---|---|---|---|
| | Jan-Jun 2026 | Jan-Jun 2025 | FY 2025 | Jan-Jun 2026 | Jan-Jun 2025 | FY 2025 | Jan-Jun 2026 | Jan-Jun 2025 | FY 2025 |
| **Total Net sales** | **124,336** | **102,026** | **243,893** | **17,396** | **15,675** | **35,200** | **141,732** | **117,701** | **279,093** |
| Raw mtrl and consumables used | -14,811 | -8,064 | -24,643 | -2,246 | -1,921 | -3,925 | -17,057 | -9,985 | -28,568 |
| Gross profit | 109,525 | 93,962 | 219,250 | 15,150 | 13,754 | 31,275 | 124,675 | 107,716 | 250,525 |
| Gross profit % | 88.1% | 92.1% | 89.9% | 87.1% | 87.7% | 88.9% | 88.0% | 91.5% | 89.8% |

## DEFINITION OF KEY PERFORMANCE INDICATORS REPORTED

Alternative performance measures (APM) are financial measurements that cannot be directly discerned or derived from financial statements. These financial measurements are intended to help the company management and investors to analyze the group's performance. Investors should view these alternative key performance indicators as a complement to the financial statements prepared in accordance with IFRS.

| | |
|---|---|
| **Order intake** | The value of orders received during the period. |
| **Net sales** | Sales of products and services are normally recognized in connection with delivery to customers, depending on the terms of delivery. Services, software, and projects that run over several periods are recognized as net sales over time. |
| **Order book** | Amount of not yet delivered products and services. |
| **Order intake rolling 12 months** | Mentice has had individually strong quarters, and it is important to view performance over time and not solely for an individual quarter. |
| **Net sales rolling 12 months** | Mentice has had individually strong quarters, and it is important to view performance over time and not solely for an individual quarter. |
| **Gross profit** | Net sales with deduction for raw materials and consumables used and depreciation of rented assets. |
| **Gross profit margin** | Gross profit as a part of net sales. |
| **EBITDA** | Earnings before Interest, Taxes, Depreciation and Amortization. This key performance indicator demonstrates the earning power of the business from operating activities without considering the capital structure and tax situation. |
| **EBITDA margin** | EBITDA as part of sales. The measure is used to measure operating profitability, independent of financing, impairment and depreciation. |
| **EBITDA rolling 12 months** | Mentice has repeatedly had individual strong quarters, and it is therefore important to continuously see developments over time and not just focus on individual quarters. |
| **Employees** | Number of employees excludes in-house consultants |
| **RTM** | Rolling Twelve Months. |

# FINANCIAL TARGETS, SHORT TO MEDIUM TERM

## REVENUE GROWTH

20-30% annual growth in net sales.

## PROFITABILITY

20% EBITDA margin within three years with a longer-term target of 30%.

# ABOUT MENTICE

## BUSINESS OPERATIONS

Mentice is a company that offers high-technology solutions for simulation to the medical sector with a focus on the fast-growing market for endovascular procedures. Mentice simulators are used to educate, train, and improve the practitioners' skills in different types of interventions and when introducing new clinical instruments. The company offers "flight simulations" for physicians and clinical teams to provide practitioners with experiences as realistic as possible. Headquartered in Gothenburg, Sweden, Mentice has a strong global presence with companies established in the US, Japan, Spain, and China.

## BUSINESS IDEA

Mentice business idea is to assist with the aim to reduce deaths, injuries and costs resulting from medical errors and inefficiencies and ultimately to reduce risk of harm to patients. By developing and providing innovative and realistic training tools, the company will help to improve the clinical skills of doctors and reduce the risk of needless errors. Medical errors are a major problem for society, come at a large cost, and are the third most common cause of death in the USA, behind heart disease and cancer. Close integration with health services and the rest of the medical device industry is vital to promote innovative solutions that enhance the simulation experience.

Sustainability, social, and environmental issues are a core element of Mentice code of conduct and its operations. Mentice has a strong focus on continuing innovation of the products offered and on taking simulation to new heights to offer the best possible solutions for customers at hospitals, clinics, universities and in research groups as well as in the medical device industry. The company has clear ambitions and principles to take economic, social, and environmental responsibility.

## PURPOSE

Mentice purpose is to reduce deaths, injuries and costs resulting from medical errors and inefficiencies by developing innovative and inspirational tools for the improvement of clinical skills.

## VISION

Mentice vision is to lead endovascular care to the highest standards of patient safety and performance.

## MISSION

We believe medical technology helps to improve patient outcomes and clinical performance. Our mission is to improve operational efficiency and patient outcomes by introducing innovative solutions that eliminate proficiency barriers.

# LEADERSHIP BUILT ON INNOVATION AND PROVEN RESULTS

A market-leading position supported by scientific evidence, technology leadership and long-term competitive advantages.

**27+**

More than 27 years of proven technology leadership in interventional simulation.

**140+**

140 scientific publications support the clinical evidence behind our solutions.

**50**

A portfolio of 50 patents protects our technology and strengthens our competitive position.

**>50%**

Market-leading position with more than 50% market share in endovascular simulation.

# FINANCIAL CALENDAR

| | |
|---|---|
| **INTERIM REPORT JUL - SEP 2026** | **NOVEMBER 10, 2026** |
| **YEAR END Q4-REPORT 2026** | **FEBRUARY 18, 2027** |
| **ANNUAL REPORT 2026** | **APRIL 22, 2027** |

Mentice interim reports and annual reports are available on www.mentice.com